Literature DB >> 10713674

Genetic variants of CYP19 (aromatase) and breast cancer risk.

V N Kristensen1, N Harada, N Yoshimura, E Haraldsen, P E Lonning, B Erikstein, R Kåresen, T Kristensen, A L Børresen-Dale.   

Abstract

The effect of a SNP in exon 10 of CYP19 on tumor mRNA levels and splice variants were studied and correlated with clinical parameters and risk of breast cancer. In the vast majority of breast cancers, the estrogen levels modulate the tumor growth and depend on the activity of CYP19. Patients (n=481) and controls (n=236) were genotyped by T-tracks in a single sequencing reaction (SSR). The frequency of TT genotypes was significantly higher in patients versus controls (P=0.007) particularly among those with stage III and IV disease (P=0.004) and with tumors larger than 5 cm (P=0.001). A significant association between presence of the T allele and the level of aromatase mRNA in the tumors was observed (P=0.018), as well as with a switch from adipose promoter to ovary promoter (P=0. 004). Previously, we reported a rare polymorphic allele of CYP19 (repeat (TTTA)12) to be significantly more frequent in breast cancer patients than in controls. Here we describe another polymorphism, a C - T substitution in exon 10 of the CYP19 gene which is in strong linkage disequilibrium with the (TTTA)n polymorphism but with higher frequency of the variant allele. Our data suggest that the T-allele of the CYP19 gene is associated with a 'high activity' phenotype. Oncogene (2000) 19, 1329 - 1333.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10713674     DOI: 10.1038/sj.onc.1203425

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  37 in total

1.  Functional variable number of tandem repeats variation in the promoter of proto-oncogene PTTG1IP is associated with risk of estrogen receptor-positive breast cancer.

Authors:  Chan Xiang; Haidong Gao; Lei Meng; Zhaoyu Qin; Rong Ma; Yang Liu; Yan Jiang; Chengxue Dang; Li Jin; Fuchu He; Haijian Wang
Journal:  Cancer Sci       Date:  2012-04-12       Impact factor: 6.716

Review 2.  Structural and functional characterization of aromatase, estrogen receptor, and their genes in endocrine-responsive and -resistant breast cancer cells.

Authors:  Hei Jason Chan; Karineh Petrossian; Shiuan Chen
Journal:  J Steroid Biochem Mol Biol       Date:  2015-08-13       Impact factor: 4.292

3.  A comprehensive examination of CYP19 variation and risk of breast cancer using two haplotype-tagging approaches.

Authors:  Janet E Olson; James N Ingle; Cynthia X Ma; Linda L Pelleymounter; Daniel J Schaid; V Shane Pankratz; Robert A Vierkant; Zachary S Fredericksen; Yanhong Wu; Fergus J Couch; Celine M Vachon; Thomas A Sellers; Richard M Weinshilboum
Journal:  Breast Cancer Res Treat       Date:  2006-09-27       Impact factor: 4.872

4.  Association between single-nucleotide polymorphisms in hormone metabolism and DNA repair genes and epithelial ovarian cancer: results from two Australian studies and an additional validation set.

Authors:  Jonathan Beesley; Susan J Jordan; Amanda B Spurdle; Honglin Song; Susan J Ramus; Suzanne Kruger Kjaer; Estrid Hogdall; Richard A DiCioccio; Valerie McGuire; Alice S Whittemore; Simon A Gayther; Paul D P Pharoah; Penelope M Webb; Georgia Chenevix-Trench
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2007-12       Impact factor: 4.254

5.  SNPs associated with molecular subtypes of breast cancer: on the usefulness of stratified Genome-wide Association Studies (GWAS) in the identification of novel susceptibility loci.

Authors:  Vessela N Kristensen; Anne-Lise Børresen-Dale
Journal:  Mol Oncol       Date:  2008-03-06       Impact factor: 6.603

6.  Two estrogen-related variants in CYP19A1 and endometrial cancer risk: a pooled analysis in the Epidemiology of Endometrial Cancer Consortium.

Authors:  Veronica Wendy Setiawan; Jennifer A Doherty; Xiao-Ou Shu; Mohammad R Akbari; Chu Chen; Immaculata De Vivo; Angela Demichele; Montserrat Garcia-Closas; Marc T Goodman; Christopher A Haiman; Susan E Hankinson; Brian E Henderson; Pamela L Horn-Ross; James V Lacey; Loic Le Marchand; Douglas A Levine; Xiaolin Liang; Jolanta Lissowska; Galina Lurie; Monica McGrath; Steven A Narod; Timothy R Rebbeck; Giske Ursin; Noel S Weiss; Yong-Bing Xiang; Hannah P Yang; Wei Zheng; Sara H Olson
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2009-01       Impact factor: 4.254

7.  CYP19A1 polymorphisms are associated with bone mineral density in Chinese men.

Authors:  Xiumei Hong; Yi-Hsiang Hsu; Henry Terwedow; Lester M Arguelles; Genfu Tang; Xue Liu; Shanchun Zhang; Xin Xu; Xiping Xu
Journal:  Hum Genet       Date:  2007-01-11       Impact factor: 4.132

8.  An aromatase polymorphism modulates the relationship between weight and estradiol levels in obese men.

Authors:  Ahmad Hammoud; Douglas T Carrell; A Wayne Meikle; Yuanpei Xin; Steven C Hunt; Ted D Adams; Mark Gibson
Journal:  Fertil Steril       Date:  2009-12-11       Impact factor: 7.329

9.  A polymorphism at the 3'-UTR region of the aromatase gene defines a subgroup of postmenopausal breast cancer patients with poor response to neoadjuvant letrozole.

Authors:  Zaida Garcia-Casado; Angel Guerrero-Zotano; Antonio Llombart-Cussac; Ana Calatrava; Antonio Fernandez-Serra; Amparo Ruiz-Simon; Joaquin Gavila; Miguel A Climent; Sergio Almenar; Jose Cervera-Deval; Josefina Campos; Carlos Vazquez Albaladejo; Antonio Llombart-Bosch; Vicente Guillem; Jose A Lopez-Guerrero
Journal:  BMC Cancer       Date:  2010-02-09       Impact factor: 4.430

10.  Rs1008805 polymorphism of CYP19A1 gene is associated with the efficacy of hormone therapy in stage I-II and operable stage III breast cancer.

Authors:  Xiying Shao; Lei Luo; Yong Guo; Xiaohong Xu; Dehou Deng; Jianguo Feng; Yuheng Ding; Hanzhou Mou; Ping Huang; Lei Shi; Yuan Huang; Weiwu Ye; Caijin Lou; Zhanhong Chen; Yabing Zheng; Xiaojia Wang
Journal:  Oncol Lett       Date:  2017-09-18       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.